View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 11, 2020

Sanofi and Regeneron to assess Kevzara to treat Covid-19

Sanofi and Regeneron Pharmaceuticals have plans to initiate clinical trials of rheumatoid arthritis drug, called Kevzara, for the treatment of Covid-19 symptoms.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Sanofi and Regeneron Pharmaceuticals have plans to initiate clinical trials of rheumatoid arthritis drug Kevzara for the treatment of Covid-19 symptoms.

The companies intend to launch testing within weeks, reported the Wall Street Journal.

According to the news agency, the companies’ efforts are part of the research on identifying existing drugs that may help address the lungs and respiratory system damage caused by the immune system’s response to coronavirus.

The US Food and Drug Administration (FDA) approved Kevzara in 2017 to treat rheumatoid arthritis. The drug is part of Sanofi and Regeneron’s ongoing antibody partnership.

In December, the companies revised the partnership, which will potentially provide Sanofi with exclusive rights to Kevzara globally.

Regeneron chief scientific officer George Yancopoulos was quoted as saying: “The goal would be in the next couple of weeks to have the trial up and running, and in weeks to months after that to have the data.”

This announcement comes within days after China approved Roche’s rheumatoid arthritis drug Actemra (tocilizumab) to treat patients developing severe complications from Covid-19.

Last month, Regeneron expanded its ongoing partnership with the US Department of Health and Human Services (HHS) to develop Covid-19 treatments.

The company agreed to work with the Biomedical Advanced Research and Development Authority (BARDA) at HHS’ Office of the Assistant Secretary for Preparedness and Response (ASPR) to develop monoclonal antibodies against the virus.

Regeneron will use its monoclonal antibody discovery platform VelocImmune to create the monoclonal antibodies.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology